Endoplasmic Reticulum Localization Signals for Targeted Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Delivering high molecular weight compounds, such as polynucleotides and polypeptides, to specific subcellular compartments within cells is challenging due to their inability to diffuse across membranes and their tendency to be degraded in lysosomes, leading to low efficacy at their site of action, especially in the presence of multidrug resistance in cancer cells.
Innovation Solution
Development of novel monomeric and multimeric endoplasmic reticulum localization signals that can be used to direct polypeptides and therapeutics to the endoplasmic reticulum by modifying existing proteins through truncation or amino acid substitution, creating chimeric signals with enhanced localization capabilities, and linking these signals to therapeutic molecules or experimental compounds.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If high molecular weight compounds are used as therapeutics, then selective uptake to specific cells can be achieved through affinity binding partners, but the compounds cannot diffuse across membranes and remain separated from the cellular cytoplasm by biological membranes
Solution Approach 1:
The patent uses affinity binding partners (such as antibodies or ligands) as intermediaries to facilitate the delivery of high molecular weight compounds to specific cells. These binding partners recognize and bind to receptors on the target cell surface, enabling selective uptake through receptor-mediated endocytosis while overcoming the inherent inability of large molecules to passively diffuse across membranes.
2Ease of operation
If endocytosis is used to internalize high molecular weight material, then cellular uptake can occur, but the material is delivered to the lysosome where it is quickly degraded by lysosomal enzymes
Solution Approach 1:
The patent exploits the lysosomal degradation pathway by incorporating lysosome-resistant formulations or protective mechanisms that convert the potentially harmful lysosomal environment into a beneficial delivery route. The lysosome serves as a controlled release compartment where the therapeutic payload is protected during transit and then released at the intended target site within the cell, rather than being immediately degraded.
3Ease of operation
If small molecules are used as drugs, then they can diffuse across plasma membranes to reach their site of action, but multidrug resistance actively effluxes drugs from cells with MDR
Solution Approach 1:
The patent changes the physical and chemical parameters of the therapeutic agent by using high molecular weight compounds with specific surface properties and affinity binding partners. This parameter change allows the therapeutic to exploit receptor-mediated endocytosis pathways rather than passive diffusion, thereby avoiding efflux pumps that target small molecule drugs in multidrug-resistant cells.
4Reliability
If delivery to desired subcellular compartment is improved, then therapeutic efficacy increases, but the complexity of targeting and delivery mechanisms increases
Solution Approach 1:
The patent segments the delivery system into distinct functional modules: an affinity binding partner for target cell recognition, a high molecular weight carrier molecule for protection and delivery, and a therapeutic payload. This segmentation allows each component to be optimized independently and facilitates modular design of delivery systems with varying specificities and payloads while maintaining overall system efficacy.
Data Source
AI summary
The invention relates to cellular localization signals. In particular, the invention relates to endoplasmic reticulum localization signals in monomeric or multimeric form. The localization signals are utilized as research tools or are linked to therapeutics. Disclosed are methods of making and using polypeptides and modified polypeptides as signals to localize therapeutics, experimental compounds, peptides, proteins and/or other macromolecules to the endoplasmic reticulum of eukaryotic cells. The polypeptides of the invention optionally include linkage to reporters, epitopes and/or other experimental or therapeutic molecules. The invention also encompasses polynucleotides encoding the localization signals and vectors comprising these polynucleotides.